Saturday, January 30, 2010 11:27:44 AM
"the company's new gene-based molecular diagnostic test for prostate cancer,which has successfully completed it’s Phase III double-blind clinical trial and is now ready for commercialization by Clarient."
This fact ALONE will bring the Big investors In...imo...even if there is more share infusion!
This one area of HDVY could take them way North and keep them there ...in the Black!
The article doesn't mention anything about the Quest and Abbott deals.
BioMedReports will be releasing a more in depth report on Monday which will surely at least partially focus on the deals with Quest and Abbott.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46077440
Recent HDVY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 07:10:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:13:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 07:53:39 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM